Seeking Alpha

An FDA panel is due to vote this week on whether to lift the restrictions on Avandia,...

An FDA panel is due to vote this week on whether to lift the restrictions on Avandia, GlaxoSmithKline's (GSK +0.3%) former blockbuster diabetes pill whose sales plummeted after the agency said in 2010 that it could only be used only in rare cases due to fears that it caused heart attacks. Following a new positive analysis of old data, two panels will decide whether to remove, modify or leave Avandia's safety restrictions in place, or withdraw the drug entirely.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs